BioNTech
BNTX
281 hedge funds and large institutions have $4.36B invested in BioNTech in 2026 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 93 increasing their positions, 71 reducing their positions, and 30 closing their positions.
43% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 30
31% more repeat investments, than reductions
Existing positions increased: 93 | Existing positions reduced: 71
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
3% more funds holding
Funds holding: 272 → 281 (+9)
3% more capital invested
Capital invested by funds: $4.22B → $4.36B (+$141M)
0.35% less ownership
Funds ownership: 18.91% → 18.55% (-0.35%)
30% less call options, than puts
Call options by funds: $117M | Put options by funds: $166M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$175M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$95.5M |
| 3 |
Goldman Sachs
New York
|
+$46.4M |
| 4 |
DCP
Davern Capital Partners
Ny,
New York
|
+$42.3M |
| 5 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$39.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Investment Management
Baltimore,
Maryland
|
-$357M |
| 2 |
Flossbach Von Storch
Cologne,
Germany
|
-$137M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$55.2M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$39.2M |
| 5 |
BNP Paribas Financial Markets
Paris,
France
|
-$31.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
301
SEI Investments
Oaks,
Pennsylvania
| – | -$220K | -2,469 | Closed |
|
|
BBVA
302
Banco Bilbao Vizcaya Argentaria
Madrid,
Spain
| – | -$209K | -2,405 | Closed |
|
|
QCG
303
Quadrant Capital Group
Cincinnati,
Ohio
| – | -$183K | -2,054 | Closed |
|
|
BC
304
Bayforest Capital
London,
United Kingdom
| – | -$113K | -1,275 | Closed |
|
|
DIP
305
DT Investment Partners
Chadds Ford,
Pennsylvania
| – | -$44.4K | -500 | Closed |
|
|
MCM
306
MAI Capital Management
Independence,
Ohio
| – | -$14K | -158 | Closed |
|
|
ASN
307
Advisory Services Network
Atlanta,
Georgia
| – | -$8.89K | -100 | Closed |
|
|
JSAM
308
J. Safra Asset Management
New York
| – | -$6.84K | -77 | Closed |
|
|
SWP
309
Strategic Wealth Partners
Independence,
Ohio
| – | -$3.73K | -42 | Closed |
|
|
CMP
310
Coston McIsaac & Partners
Bar Harbor,
Maine
| – | -$1K | -20 | Closed |
|
|
SEP
311
Signature Equity Partners
Columbus,
Ohio
| – | -$267 | -3 | Closed |
|
BNTX Hedge Fund Activity: Q2 2026 in Review
281 of the 8,279 institutional investors tracked by Wall St. Rank reported a position in BioNTech (BNTX) for Q2 2026, worth a combined $4.36B — up 3.4% from $4.22B a quarter earlier.
Buyers outnumbered sellers: 43 funds opened new BNTX positions and 30 closed out — a net gain of 13 holders — while 93 added to existing stakes and 71 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $175M. The largest seller was T. Rowe Price Investment Management, cutting an estimated $357M.
- 281 institutional investors held BioNTech (BNTX) as of Q2 2026, up from 272 in Q1 2026.
- Funds reported $4.36B of BioNTech stock for Q2 2026, up 3.4% quarter-over-quarter.
- 43 funds opened new BioNTech positions in Q2 2026 and 30 closed out, a net change of +13 holders.
- The largest BioNTech buyer in Q2 2026 was Fidelity Investments, an estimated $175M added.
- The largest BioNTech seller in Q2 2026 was T. Rowe Price Investment Management, an estimated $357M sold.
Based on aggregated 13F filings for Q2 2026.